IMMUNE CHECKPOINT INHIBITORS
Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
In a review of the Mayo Clinic database for all cancer patients who received an immune checkpoint inhibitor (ICI), 80 patients (2.4%) experienced cardiovascular immune-related adverse events. Multivariable-adjusted hazard ratios for ICI-induced myocarditis were 5.2 (95% CI 1.4-18.7, p = 0.01) among those with a history of heart failure and 4.06 (95% CI 1.15-14.3, p = 0.03) among those with a history of acute coronary syndrome.
American Journal of CardiologyMeet the Faculty
Videos
-
Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: Incidence and Patient Risk Factors
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: The Pharmacist Perspective
